72
Participants
Start Date
July 31, 2006
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
Thymosin Beta 4
There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
Placebo
There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
Chirurgia Vascolare, Bologna
Università degli Studi di Napoli - Federico II, Naples
Azienda Ospedaliera di Padova, Padua
Unità Operativa di Angiologia Azienda Ospedaliera di Padova, Padua
Istituto Dermopatico dell'Immacolata (IDI), Rome
Klinika Chirurgii Naczyń i Angiologii, Lublin
Klinika Chirurgii Ogólnej i Naczyniowej,, Szczecin
Oddział Angiologiczny, Wroclaw
sigma-tau i.f.r. S.p.A.
INDUSTRY
RegeneRx Biopharmaceuticals, Inc.
INDUSTRY